Drug Profile

OCE 205

Alternative Names: OCE-205

Latest Information Update: 19 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ocelot Bio
Class Peptides
Mechanism of Action Vasopressin 1a receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hepatorenal syndrome; Ascites
New Molecular Entity Yes

Highest Development Phases

Phase II Hepatorenal syndrome
Phase I Ascites

Most Recent Events

05 Jun 2024 Efficacy, pharmacokinetics and adverse event data from a phase II trial in Hepatorenal syndrome presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
30 Apr 2024 Phase-I clinical trials in Ascites IV) before April 2024 (Ocelot Bio pipeline, April 2024)
21 Dec 2023 Ocelot Bio completes a phase II trial in Hepatorenal syndrome in USA, Canada (IV) (NCT05309200)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com